Scholarlink

Objectives <p>To compare drug-eluting transarterial chemoembolization (DE-TACE) followed by systemic chemotherapy versus systemic chemotherapy alone for advanced lung adenocarcinoma that has progressed after targeted therapy.</p> Materials and methods <p>All patients undergoing DE-TACE followed by systemic chemotherapy (DE-TACE group) or systemic chemotherapy alone (chemotherapy group) for stage III-IV lung adenocarcinoma from January 2018 to January 2022 were screened. On day 1 of each 21-day cycle, patients received pemetrexed (500&#xa0;mg/m<sup>2</sup>) and cisplatin (75&#xa0;mg/m<sup>2</sup>). Patients in the DE-TACE group received cisplatin (75&#xa0;mg/m<sup>2</sup>) and gemcitabine (600&#xa0;mg/m<sup>2</sup>) via the feeding arteries and then embolization using drug-eluting beads carrying gemcitabine (400&#xa0;mg). DE-TACE was repeated if deemed necessary based on CT examination three weeks later. Overall survival (OS) and treatment-emergent adverse events (TEAEs) were compared in the overall cohort, as well as propensity score-matched (PSM) cohort (1:1 ratio with 0.05 caliper width).</p> Results <p>The final analysis included 62 and 69 patients in the chemotherapy and DE-TACE groups, respectively. Within the 49-month median follow-up, the median OS was 18.3 months and 33.6 months in the chemotherapy and DE-TACE groups, respectively, with a hazard ratio (HR) of 0.18 (95% CI 0.1–0.32; <i>P</i> &lt; 0.001). In the PSM analysis (36 patients per group), the median OS was 18.3 and 33.1 months in the chemotherapy and DE-TACE groups, respectively (HR 0.11, 95% CI 0.05–0.26; <i>P</i> &lt; 0.001). The rate of grade 3 or higher TEAEs in the PSM analysis was 44.4% (16/36) in the chemotherapy group versus 5.6% (2/36) in the DE-TACE group (<i>P</i> &lt; 0.001).</p> Conclusion <p>Compared to chemotherapy alone, DE-TACE followed by chemotherapy was associated was associated with significantly prolonged overall survival and substantially reduced high-grade treatment-related toxicity in patients with lung adenocarcinoma that progressed after targeted therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug-eluting TACE plus systemic chemotherapy versus systemic chemotherapy alone in advanced lung adenocarcinoma: a PSM study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • LinQiang Lai,
  • KeJun Gu,
  • DengKe Zhang,
  • ZhiCheng Jin,
  • XiaoFei Ye,
  • Fei Ye,
  • WeiWen Li,
  • YongHui Wang,
  • JingJing Song,
  • JianSong Ji,
  • JianFei Tu

摘要

Objectives

To compare drug-eluting transarterial chemoembolization (DE-TACE) followed by systemic chemotherapy versus systemic chemotherapy alone for advanced lung adenocarcinoma that has progressed after targeted therapy.

Materials and methods

All patients undergoing DE-TACE followed by systemic chemotherapy (DE-TACE group) or systemic chemotherapy alone (chemotherapy group) for stage III-IV lung adenocarcinoma from January 2018 to January 2022 were screened. On day 1 of each 21-day cycle, patients received pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Patients in the DE-TACE group received cisplatin (75 mg/m2) and gemcitabine (600 mg/m2) via the feeding arteries and then embolization using drug-eluting beads carrying gemcitabine (400 mg). DE-TACE was repeated if deemed necessary based on CT examination three weeks later. Overall survival (OS) and treatment-emergent adverse events (TEAEs) were compared in the overall cohort, as well as propensity score-matched (PSM) cohort (1:1 ratio with 0.05 caliper width).

Results

The final analysis included 62 and 69 patients in the chemotherapy and DE-TACE groups, respectively. Within the 49-month median follow-up, the median OS was 18.3 months and 33.6 months in the chemotherapy and DE-TACE groups, respectively, with a hazard ratio (HR) of 0.18 (95% CI 0.1–0.32; P < 0.001). In the PSM analysis (36 patients per group), the median OS was 18.3 and 33.1 months in the chemotherapy and DE-TACE groups, respectively (HR 0.11, 95% CI 0.05–0.26; P < 0.001). The rate of grade 3 or higher TEAEs in the PSM analysis was 44.4% (16/36) in the chemotherapy group versus 5.6% (2/36) in the DE-TACE group (P < 0.001).

Conclusion

Compared to chemotherapy alone, DE-TACE followed by chemotherapy was associated was associated with significantly prolonged overall survival and substantially reduced high-grade treatment-related toxicity in patients with lung adenocarcinoma that progressed after targeted therapy.